Zhitong Financial APP learned that on Aug. 13, the International Department of China Securities Regulatory Commission (CSRC) disclosed the "approval of overseas initial public offerings (including common shares, preferred shares and other stocks and stock derivatives) submitted by Pharmaceutical Jie Ankang (Nanjing) Technology Co., Ltd.". Once accepted, it means that Pharma Jie Ankang may soon submit its prospectus on the Hong Kong Stock Exchange.

It is reported that Pharmaceutical Jie Ankang, founded in 2014 and headquartered in Nanjing, Jiangsu Province, is an innovative small molecule new drug research and development company, mainly developing innovative drugs that do not meet clinical needs and have obvious differences. The company had previously completed the latest round of financing led by CPE Yuanfeng and China transfer Fund, Sixty Degree Capital, China Merchants Capital, Jinpu Health Fund, Cornerstone Capital and Jiangsu Ruihua Investment Fund in July 2021, except for this round of financing. Previous rounds of investors include: medicine and Stone Technology, CIC Entrepreneurship, Nanjing Fengling, CIC Investment, Haisong Medical Fund, Eastern Handson, Changjiang Guohong Investment, Ningbo Zirong Beta, Eagle Alliance Investment and so on.